Correvio Pharma Corp (CORV) Stock Price & Overview

NASDAQ:CORV

Current stock price

0.4199
+0 (+0.82%)
At close:
0.4197
0 (-0.05%)
After Hours:

The current stock price of CORV is 0.4199 null. Today CORV is up by 0.82%. In the past month the price increased by 1.57%. In the past year, price decreased by -81.25%.

CORV Key Statistics

52-Week Range0.21 - 2.79
Current CORV stock price positioned within its 52-week range.
1-Month Range0.3632 - 0.4287
Current CORV stock price positioned within its 1-month range.
Market Cap
27.794M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.79
Dividend Yield
N/A

CORV Stock Performance

Today
+0.82%
1 Week
+0.19%
1 Month
+1.57%
3 Months
-8.72%
Longer-term
6 Months -79.72%
1 Year -81.25%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

CORV Stock Chart

Correvio Pharma Corp / CORV Daily stock chart

CORV Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to CORV. When comparing the yearly performance of all stocks, CORV is a bad performer in the overall market: 95.72% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
CORV Full Technical Analysis Report

CORV Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CORV. CORV may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CORV Full Fundamental Analysis Report

CORV Earnings

Next Earnings DateN/A
Last Earnings DateN/A
CORV Earnings History

CORV Forecast & Estimates


Analysts
Analysts60
Price TargetN/A
EPS Next Y16.46%
Revenue Next YearN/A
CORV Forecast & Estimates

CORV Financial Highlights

Over the last trailing twelve months CORV reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 11.24% compared to the year before.


Income Statements
Revenue(TTM)32.63M
Net Income(TTM)-35.18M
Industry RankSector Rank
PM (TTM) -107.81%
ROA -59.26%
ROE N/A
Debt/Equity 21.5
Chartmill High Growth Momentum
EPS Q2Q%-15%
Sales Q2Q%-4.82%
EPS 1Y (TTM)11.24%
Revenue 1Y (TTM)13.81%
CORV financials

CORV Ownership

Ownership
Inst Owners7.3%
Shares66.19M
Float61.31M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
CORV Ownership

About CORV

Company Profile

Correvio Pharma Corp. operates as a pharmaceutical company. It develops and discovers cardiovascular drugs for the treatment of atrial arrhythmia, congestive heart failure and bacterial skin infections. The company's product portfolio includes BRINAVESS(R), AGGRASTAT(R), ESMOCARD(R), ESMOCARDLYO(R), EXEMBOL(R) and XYDALBA(TM). Correvio Pharma Corp., formerly known as Correvio Pharma Corp., is based in Vancouver, Canada.

Company Info

Correvio Pharma Corp

1441 Creekside Drive 6th Floor

Vancouver A1 V6J 4S7

CEO: Mark Corrigan

Phone: 604-677-6905

Correvio Pharma Corp / CORV FAQ

Can you describe the business of Correvio Pharma Corp?

Correvio Pharma Corp. operates as a pharmaceutical company. It develops and discovers cardiovascular drugs for the treatment of atrial arrhythmia, congestive heart failure and bacterial skin infections. The company's product portfolio includes BRINAVESS(R), AGGRASTAT(R), ESMOCARD(R), ESMOCARDLYO(R), EXEMBOL(R) and XYDALBA(TM). Correvio Pharma Corp., formerly known as Correvio Pharma Corp., is based in Vancouver, Canada.


What is the current price of CORV stock?

The current stock price of CORV is 0.4199 null. The price increased by 0.82% in the last trading session.


Does Correvio Pharma Corp pay dividends?

CORV does not pay a dividend.


What is the ChartMill technical and fundamental rating of CORV stock?

CORV has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Should I buy CORV stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CORV.


What is Correvio Pharma Corp worth?

Correvio Pharma Corp (CORV) has a market capitalization of 27.79M null. This makes CORV a Nano Cap stock.